Keyphrases
A1 Receptor
23%
Glucagon
33%
Glucagon-like
100%
Glucose-dependent Insulinotropic Polypeptide
36%
Glycemic Control
21%
Hemoglobin A1c (HbA1c)
18%
Incretin Hormones
15%
Insulin
30%
Insulin Resistance
21%
Insulin Secretion
22%
Insulin Sensitivity
25%
Insulin Therapy
16%
Insulinotropic Effects
17%
Liraglutide
37%
Metformin
15%
Non-diabetic
15%
Obesity
26%
Placebo
18%
Receptor Agonist
22%
Roux-en-Y Gastric Bypass
52%
Skeletal muscle
21%
Type 1 Diabetes Mellitus (T1DM)
31%
Type 2 Diabetes Mellitus (T2DM)
58%
Type 2 Diabetic Patients
54%
Type I Diabetes
30%
Weight Loss
33%
Medicine and Dentistry
Beta Cell
22%
Cell Function
20%
Diabetes
20%
Diabetes Mellitus
31%
Gastric Bypass Surgery
18%
Gastric Inhibitory Polypeptide
30%
Glucagon
15%
Glucagon Like Peptide 1
70%
Glucagon-Like Peptide-1 Agonist
16%
Glucose Metabolism
16%
Glucose Tolerance
18%
Glycemic Control
18%
Incretin
22%
Insulin Release
29%
Insulin Resistance
18%
Insulin Sensitivity
26%
Liraglutide
20%
Maturity Onset Diabetes of the Young
49%
Patient with Type 2 Diabetes
29%
Placebo
21%
Roux-en-Y Gastric Bypass
50%
Secretion (Process)
25%
Biochemistry, Genetics and Molecular Biology
Gastric Inhibitory Polypeptide
34%
Glucagon
29%
Glucagon-Like Peptide-1
55%
Glucose Blood Level
23%
Human immunodeficiency virus
15%
Incretin
20%
Insulin Release
27%
Insulin Resistance
23%
Insulin Sensitivity
17%
Skeletal Muscle
18%